Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Hemlibra for Hemophilic Pseudotumor
NCT03921294Phase 4Terminated
- Sponsor
- Indiana Hemophilia and Thrombosis Center
- Start
- May 2019
- Primary completion
- Mar 2022
- Modality
- Bispecific Antibodies, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of emicizumab in hemophilic pseudotumor, sponsored by Indiana Hemophilia and Thrombosis Center. Primary endpoints: Hemostatic Efficacy Based on Hemoglobin and Hemostatic Efficacy Based on Need for Blood Transfusions. Started May 2019; status: terminated.
02
Drugs
emicizumab
03
Conditions
hemophilic pseudotumor
Beyond the preview
Go deeper on NCT03921294.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03921294.